Enrico Martin

164 Chapter 7 Table 1 Preclinical in vivo studies. Author, year Model Regimen Pathway Tissue NF1 a Outcome Growth b Survival c Metastasis d Membrane targets Johansson, 2008 XM Erlotinib + sirolimus EGFR, mTOR STS26T S NA NA Byer, 2011 OXM Tamoxifen ER ST88-14 NF1 NA NA Torres, 2011 XM Cabozantinib Multikinase (incl. MET, VEGFR2) STS26T S NA MPNST724 S NA NA Mo, 2013 AA, GEMM AMD3100 CXCR4 sMPNST NA NA NA NPcis NA NA NA Ohishi, 2013 XM Imatinib Multikinase (incl. c-Kit) HS-Sch-2 S NA NA FMS-1 NF1 NA NA NMS-2PC NF1 NA NA Brosius, 2014 OXM Tamoxifen + trifluoperazine ER, calmodulin ST88-14 NF1 NA NA STS26T S NA NA Patwardhan, 2014 XM Pexidartinib + sirolimus Multikinase (incl. c-Kit), mTOR MPNST NA NA NA Castellsague, 2015 OXM Sorafenib + doxorubicin/ sirolimus Multikinase (incl. VEGFR), mTOR NF1-001 NF1 NA NA NF1-002 NF1 NA NA SP-001 S NA NA SP-002 S NA NA S462 NF1 NA NA Lock, 2016 GEMM Cabozantinib + PD0325901 Multikinase (incl. MET, VEGFR2), MEK NPcis NA NA NA Ki, 2017 ZFM Sunitinib Multikinase (incl. VEGFR) NF1a +/ − ; NF1b −/− ;p53 m/m NA NA NA Wu, 2018 AA Sorafenib + verteporfin Multikinase (incl. VEGFR), TAZ/YAP Lats1/2 -/- NA NA NA